Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 2, 2011, Pages 513-524

  Jia, Lee ^a   Gorman, Gregory S ^b   Coward, Lori U ^b   Noker, Patricia E ^c   McCormick, David ^d   Horn, Thomas L ^d   Harder, J Brooks ^d   Muzzio, Miguel ^d   Prabhakar, Bellur ^e   Ganesh, Balaji ^e   Das Gupta, Tapas K ^f   Beattie, Craig W ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAMFORD UNIVERSITY   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d IIT RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ILLINOIS   (United States)

^f CDG Therapeutics   (United States)

Author keywords

Azurin; Chemotherapeutic; p28; Pharmacokinetics; Toxicology

Indexed keywords

AZURIN P28; DACARBAZINE; FLUOROURACIL; NSC 745104; PACLITAXEL; PEPTIDE DERIVATIVE; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG UPTAKE; FEMALE; HEART WEIGHT; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MOUSE; NEUROTOXICITY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPECIES COMPARISON; THYMUS; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR CELL; TUMOR XENOGRAFT; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AZURIN; BIOTRANSFORMATION; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICE, NUDE; NEOPLASMS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PEPTIDE FRAGMENTS; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960927023     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1518-3     Document Type: Article

References (10)

1. Gorman GS, Coward LU, Freeman L, Noker PE, Beattie CW, Jia L (2010) A novel and rapid LC/MS/MS assay for bioanalysis of azurin p28 in serum and its pharmacokinetics in mice. J Pharm Biomed Anal 53:991-996
2. L Jia X Liu 2007 The conduct of drug metabolism studies considered good practice (II): in vitro experiments Curr Drug Metab 8 822 829 18220563 10.2174/138920007782798207 1:CAS:528:DC%2BD2sXhsVahtrrP (Pubitemid 350238912)
3. L Jia PE Noker L Coward GS Gorman M Protopopova JE Tomaszewski 2006 Interspecies pharmacokinetics and in vitro metabolism of SQ109 Br J Pharmacol 147 476 485 16432511 10.1038/sj.bjp.0706650 1:CAS:528:DC%2BD28XitVCmt78%3D (Pubitemid 43355045)
4. L Jia PE Noker GA Piazza C Leuschner W Hansel GS Gorman LU Coward J Tomaszewski 2008 Pharmacokinetics and pharmacodynamics of Phor21-betaCG(ala), a lytic peptide conjugate J Pharm Pharmacol 60 1441 1448 18957164 10.1211/jpp.60.11.0004 1:CAS:528:DC%2BD1cXhsVSnu7fE
5. V Punj S Bhattacharyya D Saint-Dic C Vasu EA Cunningham J Graves T Yamada AI Constantinou K Christov B White G Li D Majumdar AM Chakrabarty TK Das Gupta 2004 Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer Oncogene 23 2367 2378 14981543 10.1038/sj.onc.1207376 1:CAS:528:DC%2BD2cXisVGks7Y%3D (Pubitemid 38496792)
6. S Rauth J Kichina A Green L Bratescu TK Das Gupta 1994 Establishment of a human melanoma cell line lacking p53 expression and spontaneously metastasizing in nude mice Anticancer Res 14 2457 2463 7872667 1:CAS:528:DyaK2MXltlejt74%3D
7. BN Taylor RR Mehta T Yamada F Lekmine K Christov A Green L Bratescu A Shilkaitis AM Chakrabarty CW Beattie TK Das Gupta 2009 Noncationic peptides obtained from azurin preferentially enter cancer cells Cancer Res 69 537 546 19147567 10.1158/0008-5472.CAN-08-2932 1:CAS:528:DC%2BD1MXltFSiuw%3D%3D
8. T Yamada AM Fialho V Punj L Bratescu TK Gupta AM Chakrabarty 2005 Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity Cell Microbiol 7 1418 1431 16153242 10.1111/j.1462-5822. 2005.00567.x 1:CAS:528:DC%2BD2MXhtVGmurvM (Pubitemid 41335246)
9. T Yamada Y Hiraoka M Ikehata K Kimbara BS Avner TK Das Gupta AM Chakrabarty 2004 Apoptosis or growth arrest: modulation of tumor suppressor p53's specificity by bacterial redox protein azurin Proc Natl Acad Sci USA 101 4770 4775 15044691 10.1073/pnas.0400899101 1:CAS:528:DC%2BD2cXjsFCjtbY%3D (Pubitemid 38469152)
10. T Yamada RR Mehta F Lekmine K Christov ML King D Majumdar A Shilkaitis A Green L Bratescu CW Beattie TK Das Gupta 2009 A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells Mol Cancer Ther 8 2947 2958 19808975 10.1158/1535-7163.MCT-09-0444 1:CAS:528: DC%2BD1MXht1Cqur%2FI